Lublin, Fred D2; Reingold, Stephen C2; Cohen, Jeffrey A2; Cutter, Gary R2; Sørensen, Per Soelberg3; Thompson, Alan J2; Wolinsky, Jerry S2; Balcer, Laura J2; Banwell, Brenda2; Barkhof, Frederik2; Bebo, Bruce2; Calabresi, Peter A2; Clanet, Michel2; Comi, Giancarlo2; Fox, Robert J2; Freedman, Mark S2; Goodman, Andrew D2; Inglese, Matilde2; Kappos, Ludwig2; Kieseier, Bernd C2; Lincoln, John A2; Lubetzki, Catherine2; Miller, Aaron E2; Montalban, Xavier2; O'Connor, Paul W2; Petkau, John2; Pozzilli, Carlo2; Rudick, Richard A2; Sormani, Maria Pia2; Stüve, Olaf2; Waubant, Emmanuelle2; Polman, Chris H2
1 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet2 unknown3 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet
The 2013 revisions
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Journal review article
Neurology, 2014, Vol 83, Issue 3, p. 278-286
Clinical Trials as Topic; Consensus; Humans; Multiple Sclerosis; Societies, Medical